SCHEMBL9924134

SCHEMBL9924134

CCOC(=O)N[C@H]1CC[C@H](N/C(=N/C(=O)c2ccc(F)c(F)c2)Nc2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
DCUN1D1 Q96GG9 9/20 0.45
UBE2M P61081 8/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
EPHX2 P34913 3/20 0.44
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.42
IDH2 P48735 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206695 0.91 EPHX2 (0.46) SMN1; SMN2DCUN1D1UBE2MMEN1KMT2A
SCHEMBL9924424 0.89 TRPV1 (0.45) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL9924275 0.87 THRB (0.45) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL17206619 0.87 EPHX2 (0.48) MAPTHTTDCUN1D1UBE2MMEN1
SCHEMBL9924133 0.86 EPHX2 (0.47) MAPTHTTDCUN1D1UBE2MMEN1
SCHEMBL17206718 0.85 UBE2M (0.43) MAPTHTTSMN1; SMN2DCUN1D1UBE2M
SCHEMBL17206682 0.84 TRPV4 (0.48) MAPTHTTDCUN1D1UBE2MMEN1
SCHEMBL9924156 0.84 CHRM1 (0.45)
SCHEMBL17206685 0.84 MEN1 (0.49) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL9924143 0.82 EPHX2 (0.44) DCUN1D1UBE2MMEN1KMT2AEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed